Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alimemazine
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Lucis Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Rosemont Expands its Offering with Portfolio Acquisition from Lucis Pharma Ltd
Details : Through the acquisition, Rosemont will expand its existing portfolio and have access to a pipeline of innovative products including, alimemazine tartrate, an oral solution, used for the management of urticaria and pruritus.
Brand Name : Alimemazine Tartrate-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2023
Lead Product(s) : Alimemazine
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Lucis Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
